NEJM: Vaccine efficacy begins to decline 20 weeks after ChAdOx1-S and BNT162b2 vaccinations

The Covid -19 vaccine has been available in the UK since December 2020, and real-world research data shows that vaccination is highly effective in reducing the risk of Covid-19 and its associated serious illness and death, but the protective efficacy of the vaccine may increase over time weakened over time
.

The researchers looked at the duration of protection after completing 2 doses of the vaccine in the UK population

Covid- 19 Day researchers looked at the duration of protection after completing 2 doses of the vaccine in the UK population

After 20 weeks of prophylaxis , the ChAdOx1-S vaccine decreased to 44.
3%, and the BNT162b2 vaccine decreased to 66.
3%, of which the vaccine effectiveness decreased more for people aged 65 years or older than for those aged 40 to 64 years

Vaccine effectiveness drops 20 weeks after vaccination

The effectiveness of the vaccine decreases after 20 weeks of vaccination The effectiveness of the vaccine decreases after 20 weeks of vaccination

The study found that 20 weeks after completion of 2-dose ChAdOx1-S vaccine and BNT162b2 vaccination, the vaccine's effectiveness in preventing Covid-19-related hospitalizations and deaths declined, with greater declines in the elderly and clinically vulnerable populations
.

Twenty weeks after completion of 2-dose ChAdOx1-S vaccine and BNT162b2 vaccination, the vaccine's effectiveness in preventing Covid-19-related hospitalizations and deaths declined, with greater declines in the elderly and clinically vulnerable populations
.
Twenty weeks after completion of 2-dose ChAdOx1-S vaccine and BNT162b2 vaccination, the vaccine's effectiveness in preventing Covid-19-related hospitalizations and deaths declined, with greater declines in the elderly and clinically vulnerable populations
.

Original Source:
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
Leave a comment here